NCT02030834View on ClinicalTrials.gov

Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 5, 2014

Primary Completion Date

September 16, 2019

Study Completion Date

September 1, 2020

Conditions

Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas

Interventions

BIOLOGICAL

CART-19

Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors

lead

University of Pennsylvania

OTHER